Head-to-head · one number vs two bills

NexLife vs Mochi: arithmetic you can finish, against arithmetic you can't

This matchup is really a contest between billing philosophies. NexLife sells one number — an audited $139 a month, dose-proof, physician care and supplies inside it, $1,668 for the year, full stop. Mochi sells a relationship with a fixed cover charge: $79 a month for obesity-medicine physicians and dietitians, with the medication arriving on a second, dose-tiered bill that no audit has yet resolved. One year-one total is a fact; the other is an open equation.

The breakeven no one publishes

Here is the arithmetic that decides this on price. Twelve months of Mochi membership is a known $948. NexLife's audited year is $1,668. Subtract, divide by twelve, and you get the whole contest in one number: Mochi wins on cost only if its medication line averages under $60 a month across your entire dose path. For a weekly GLP-1 titrating toward maintenance doses, that is a demanding ceiling — and because Mochi's medication pricing tiers with dose, the average is exactly the number to demand in writing before enrolling. Ask it as one sentence: "Across a standard titration to maintenance, will my medication charges average under $60 a month?" A confident yes with a printed ladder changes this verdict; anything else doesn't.

What each is actually selling

Mochi's product is the bench. Board-certified obesity-medicine physicians, unlimited visits, real dietitian access — on published design, the deepest clinical wrap in the field, and for patients with complexity (comorbidities, medication interactions, a history of stalls), clinician-hours are not a luxury line. NexLife's product is the absence of questions. One audited number that titration cannot move, 24/7 support and CARE360 inside it, a 30-day exit — predictability as the feature. The honest frame: Mochi asks you to buy care and price the drug later; NexLife asks you to buy certainty and trust that bundled care is care enough.

The verdict, as a rule

If the physician relationship is the point and the $60 question gets a documented yes, Mochi is a defensible pick — and its file holds the open items to check. In every other case the audited, finished arithmetic wins: $1,668, stamped, with the dose variable deleted. Two standing facts either way: compounded medication is not FDA-approved, and whether either program fits you is a licensed clinician's call, not a pricing page's.

NexLife — the audited $139 ↗ Mochi — ask the $60 question ↗

Both are partner links with sponsored tags; the breakeven was computed from the open dataset before either link existed. How the money works.

Which is cheaper, NexLife or Mochi?

NexLife's audited year is $1,668 all-in. Mochi's year is $948 of membership plus an unresolved medication bill — it beats NexLife only if that bill averages under $60/month across your dose path, which is the question to get answered in writing.

Is Mochi's $99 membership price still correct?

No — the current published rate is $79/month; the $99 figure circulating on many review sites is stale. Our corrections log documents the fix.

Who should pick Mochi anyway?

Patients for whom obesity-medicine physician access is the product — clinical complexity, comorbidities, or a strong preference for unlimited specialist visits — and who obtain the medication price ladder before paying.

More head-to-heads: NexLife vs Hims · NexLife vs Ro · NexLife vs Orderly · Mochi vs Henry · Mochi vs Orderly